NCI
Neo-Concept International Group Holdings Limited Ordinary Shares
Mentions (24Hr)
0.00% Today
Reddit Posts
Mentions
7:09 AM EDT, May 06, 2025 (Benzinga Newswire) License Expands Genprex's Portfolio of Oncology Gene Therapy Technologies AUSTIN, Texas, May 6, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive patent license agreement with UTHealth Houston granting Genprex exclusivity and commercial rights relating to its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid) for the potential treatment of glioblastoma. The subject patent is co-owned by Genprex and UTHealth Houston, and the license provides Genprex with patent exclusivity. "We are pleased to expand our portfolio of licensed patents and add a technology that uses REQORSA to treat glioblastoma," said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing. "With this license agreement, Genprex has obtained exclusive commercial rights to REQORSA in glioblastoma while also adding to our patent estate. The role of TUSC2 in lung cancer has been well established, and this latest license enables Genprex to expand the use of REQORSA into a new indication, in which the cancer can be difficult to treat and there are unmet medical needs." REQORSA may be a potential therapeutic treatment for glioblastoma. Genprex previously reported positive preclinical data on the efficacy of REQORSA in glioblastoma in October 2024 at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Research collaborators from UTHealth Houston previously reported TUSC2 as a novel tumor suppressor for glioblastoma, the most common and deadliest primary brain tumor in adults which is associated with a poor prognosis. In their latest study, UTHealth Houston researchers used patient-derived glioblastoma (GBM) cell lines and patient-derived glioma stem cell (PD-GSC) lines. REQORSA was used to restore TUSC2 expression. Write to Benzinga at editorial@benzinga.com
I’m a cancer research her who has watched half my colleagues get furloughed bc the NIH/NCI has been dissolved. That’s not political theater that’s a breaking of a fundamental federal institution that provides a service (academic biomedical research) for the greater good. And you could say the same thing about dep of education, VA hospitals, national park services, the CDC, etc
Its price hit $2+ twice in March. Although I don't know if it'll hit $2 again today but I am optimistic. Here's the news summary (by ChatGPT): The sentiment of this news is **strongly positive**, driven by promising clinical data, high clinical benefit rates, and the absence of significant safety concerns in early trial phases for REYOBIQ™. The tone is optimistic, with credible scientific and regulatory backing (NCI, CPRIT) * New **Phase 1 trial data** for REYOBIQ in Leptomeningeal Metastases (LM) shows **dose-dependent efficacy** and **high clinical benefit**: * Immune response insights from RNA sequencing suggest **apoptosis and immune activation** by Day 28. **Implications:** The data reinforces REYOBIQ’s potential as a **safe, high-dose radiotherapeutic** for a **highly fatal and underserved condition (LM)**. The lack of FDA-approved therapies for LM and the grim prognosis for these patients highlight the **market need** and **clinical urgency**. The tolerability of higher doses without significant toxicity is particularly promising.
NCI is ready for a run.. lots on enthu on stocktwits
NCI and WETH One because it’s the most obvious of pump and dumps and I regret not seeing it. The other just seems to never do anything and I’m stuck with the bag.
MMA.V, NCI.V, and NICU.V show strong growth potential due to strategic partnerships, market positioning, and resource-focused projects.
NYWKF/NCI.V looks solid. They just [landed another $22M three-year contract with 37% margins](https://finance.yahoo.com/news/ntg-clarity-secures-22m-three-120000220.html). Backlog now over $100M. Their Egypt offshore strategy is brilliant - collecting revenue in Saudi Riyal while paying expenses in Egyptian Pounds. Smart move focusing on Saudi Arabia's tech transformation. [Over 180 major companies moved their regional HQs there in first half of 2024](https://finance.yahoo.com/news/ntg-clarity-achieves-109-yoy-033156094.html) including Google and PepsiCo. Perfect timing with Vision 2030 driving massive digital infrastructure spending. 46% insider ownership shows management has skin in the game. Eight straight record quarters. Their strategy of landing long-term contracts instead of one-offs is working. Balance sheet looks way better now too. MGMNF/NICU.V also looking good after that [new copper discovery - 2.3% Cu over 13.9m](https://finance.yahoo.com/news/magna-mining-discovers-copper-zone-120000056.html). Shakespeare project is permitted for 4500tpd operation. Plus that KGHM deal gives them immediate cash flow from McCreedy West. Skip MMA.V for now until we see what that Zambian license actually means for production.
move your $$ north to Chinada - worth %40% moar [NCI.to](http://NCI.to) [VLN.to](http://VLN.to) [PPTA.to](http://PPTA.to) [GSI.to](http://GSI.to) [QTRH.TO](http://QTRH.TO) LUCA.v
TPST WETH NCI RR Please
NCI is going strong; as mentioned yesterday and today we have a PR **HONG KONG, Oct. 22, 2024 (GLOBE NEWSWIRE) --** Neo-Concept International Group Holdings Limited (Nasdaq: NCI) ("the Company") is thrilled to announce the successful completion of its transformative acquisition of the intellectual property (IP) and research and development (R&D) capabilities from its affiliate, Neo-Concept (Holdings) Company Limited ("NCH"). This strategic acquisition empowers NCI with full ownership of the esteemed "Les100Ciels" and "SIU" brands, along with all related trademarks and trade names. Additionally, the transfer includes NCH's talented R&D teams, further enhancing NCI’s potential for innovation. "This is a landmark moment for our company," said Miss Eva Siu, Chairlady and CEO of NCI. "By gaining complete control over our brand assets, we are well-equipped to drive our growth initiative, particularly in the vibrant Middle East market." NCI's Chief Financial Officer, Mr. Patrick Lau, highlighted the financial advantages of this acquisition: "This move not only simplifies our operational structure but also positions us to maximize shareholder returns as we expand our retail footprint across the globe." With the asset transfer now complete, NCI is excited to embark on this new journey, leveraging its enhanced capabilities to deliver innovative products and exceptional experiences to customers worldwide. - END -
I’m buying NCI pre-market. It’s about to make a parabolic move
$NCI is looking primed for a breakout and new HOD. 14.5 million shares have been traded so far and are growing.
Bullish on Gri, NCI, VITAK, TIRX
Waymo is a private company majority owned by Google (or to not confuse you, Alphabet). The portion not owned by Google would be NCI on Google's balance sheet.
anyone in NCI and knows wtf they do?
$NCI why’s no one following👀
Any particular reason why $NCI.V has dropped so much?
$NCI (NTG Clarity Network) is a hidden gem at the moment, in my opinion. Here's a quick DD I sent to my group of my friends not too long ago. I'm usually a lurker here, but the company seems promising. Do your own DD, would love to hear you guys' thoughts. They reported seven consecutive quarters of record-setting revenue growth. In Q2 2024, they posted a revenue of $12.49 million, a 96% increase compared to the same quarter the previous year. *Profitability*: Significant rise in profitability, with a net profit of $2.44 million in Q2 2024, which is a 250% increase from the previous year. This level of profitability is usually pretty rare in the IT services and consulting sector, especially for a company of their size (about ~200 last time I checked) *Positive Balance Sheet*: They absolutely killed it when they improved their financial health by reducing long-term debt and achieved a positive working capital. *Strategic Market Positioning*: Their growth is largely driven by its operations in Saudi Arabia, where demand for digital transformation and IT services is booming due to the country's Vision 2030 plan. They have a long-standing presence in the region, so they are very well positioned to capitalize on these trends.